Humana reported a second-quarter net income of $694 million, driven by a surge in Medicare Advantage enrollees to 7.1 million, up from 5.8 million a year ago. Despite rising medical costs industry-wide, Humana managed to keep its benefit ratio at 91.2%, in line with management's guidance, reflecting controlled medical and pharmacy expenses. The company’s revenue rose to $40.8 billion, beating Wall Street expectations, as it capitalized on operational efficiency and clinical care improvements. CEO Jim Rechtin highlighted that the company remains on track to deliver strong earnings and better health outcomes by focusing on value-based care.
Humana's stock was upgraded to Outperform by Evercore ISI following strong Q2 2026 results. The company reported adjusted earnings of $7.61 per share and revenues of $40.9 billion, both exceeding analyst expectations, driven by a 20.7% growth in medi...
Humana Inc., a health insurer focused on Medicare Advantage plans, reported a sharp decline in profit margins, with Q2 2026 pre-tax margin at 1.8%, down from 6.7% in 2020. The company targets a sustainable 3% pre-tax margin by 2028 through improving ...
Humana reported second-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $7.61 versus the expected $7.22, and revenue of $40.87 billion beating estimates. The company maintained its 2026 adjusted profit outlook ...
A securities fraud lawsuit against Humana Inc. and its former CEO and CFO is proceeding after a judge ruled key claims valid. The lawsuit alleges that from July 2022 to October 2024, Humana misled investors about rising healthcare utilization costs, ...
This week, U.S. markets focus on the Federal Reserve's July meeting, key inflation data like Core PCE, and second-quarter GDP figures, alongside major tech earnings from Microsoft, Meta, Apple, and Amazon. Rising oil prices and geopolitical tensions ...
